QL1604 Monotherapy for dMMR or MSI-H Advanced Solid Tumors

Summary

In this study, patients with previously-treated locally-advanced or metastatic mismatched repair deficient (dMMR) or microsatellite instability-high (MSI-H) colorectal carcinoma (CRC) and other solid tumors will be treated with QL1604 monotherapy.

Timeline

Start

2020-07-08

Primary completion

2022-12

Completion

2023-07

Publications

• Bi F, Dong J, Jin C, Niu Z, Yang W, He Y, Yu D, Sun M, Wang T, Yin X, Zhang R, Chen K, Wang K, Wang Z, Li W, Zhang Z, Zhang H, Guo Q, Wang X, Han L, Zhang X, Shen W, Zhang L, Ying J, Wu M, Hu W, Li Z, Li X, Feng W, Zhang B, Li L, Kang X, Guo W. Iparomlimab (QL1604) in patients with microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) unresectable or metastatic solid tumors: a pivotal, single-arm, multicenter, phase II trial. J Hematol Oncol. 2024 Nov 11;17(1):109. doi: 10.1186/s13045-024-01627-5.

Drugs

Indications